CMTR Featured Speakers

CMTR Featured Speakers
Sunday 28 June, 2020 


Robert Baloh, MD, PhD Cedars-Sinai Medical Center, Los Angeles, CA, USA
Title
Mitofusins in axonal degeneration and neuroprotection

   

Mutations in Mitofusin 2 (MFN2) cause Charcot-Marie-Tooth disease type 2A, typically with dominant inheritance. The peripheral neuropathy in CMT2A is typically early onset, and can be accompanied by a variety of neurologic features including vision loss, spastic paraparesis, and even developmental delay from altered neurodevelopment. Loss of mitochondrial dynamics (fusion, fission, movement and degradation) plays a role in the relative vulnerability of long peripheral axons, and the relative ration of MFN1 to MFN2 in different tissues likely also plays a role in the vulnerability of the nervous system relative to other tissues. Recent work has also suggested that while the balance of fission and fusion of mitochondria is important, that increasing the levels of MFN protein or function using peptides or small molecules may be more broadly neuroprotective.

 

Pascale Bomont, PhD NM-INSERM, University of Montpellier, Montpellier, France 
Title: 
Exploration of Giant Axonal Neuropathy unveils common pathological mechanisms amongst CMT diseases: the obvious and the unexpected.

Giant Axonal Neuropathy (GAN) was first described by Berg and Asbury in 1972, in a child presenting with a progressive motor and sensory neuropathy, and “giant” axons filled with abnormally packed neurofilaments in nerve biopsy. Since then, we learned that Intermediate Filament (IF) aggregation extends beyond neuronal tissues, and that GAN can subsequently spread to the central nervous system. We identified the Gigaxonin-E3 ligase as the defective protein in patients and dedicated our efforts to the elucidation of the key roles of the GAN gene in sustaining neuronal and cytoskeleton integrity. Our laboratory designed novel tools to offer a differential diagnosis between GAN and CMT forms which share common clinical and histopathological features. Moreover, we developed several biological models, from patient’s derived fibroblasts to mouse and zebrafish to decipher the pathological mechanisms in GAN. Altogether, we demonstrate that the Gigaxonin-E3 ligase is a pivotal player of tissue homeostasis, controlling essential cellular pathways of IF architecture and autophagy production. Considering the evidences of a clinical, histopathological and functional overlap between GAN and several CMT forms, we propose GAN as a CMT disease and as an important model to help understanding the complexity of CMT biology. In particular, we will focus of our recent findings on the role of Gigaxonin-E3 ligase in neuron specification through the regulation of the Sonic Hedgehog pathway, which highlight a developmental origin in GAN, and offer novel functional and therapeutic perspectives for neurodegenerative diseases.

 

CMTR Featured Speakers
Monday 29 June, 2020 


Roman Chrast, PhD, University Hospital of Würzburg, Department of Neurology, Developmental Neurobiology, Würzburg, Germany
Title: Pathogenetic Inflammation in Models for Schwann Cell-related Charcot-Marie-Tooth Disorders

     

 


Merrill Benson, MD Indiana University, Indianapolis, Indiana, USA 
Title: FAP-What's new?

  A lot has happened in the last 20 years for diagnosis and treatment of transthyretin amyloidosis. It is a good time to see where we have been, where were are, and where we should be going.

 


 

Thank you to our 2019 PNS Sponsors!